{"nctId":"NCT00968812","briefTitle":"CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride","startDateStruct":{"date":"2009-09"},"conditions":["Diabetes Mellitus, Type 2"],"count":1452,"armGroups":[{"label":"Glimepiride","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Glimepiride","Drug: Metformin"]},{"label":"Canagliflozin 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin (JNJ-28431754)","Drug: Metformin"]},{"label":"Canagliflozin 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin (JNJ-28431754)","Drug: Metformin"]}],"interventions":[{"name":"Glimepiride","otherNames":["sulfonylurea"]},{"name":"Canagliflozin (JNJ-28431754)","otherNames":[]},{"name":"Metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must have a diagnosis of type 2 diabetes\n* Body mass index (BMI) \\>=22 to \\<=45 kg/m2, at screening\n* Patients must be taking a stable dosage of metformin as monotherapy at screening\n* Patients must have a HbA1c between \\>=7% and \\<=9.5% at Week 2\n* Patients must have a fasting plasma glucose (FPG) \\<=270 mg/dL (15 mmol/L) at Week -2\n\nExclusion Criteria:\n\n* Patients having prior exposure or known contraindication or suspected hypersensitivity to JNJ-28431754, glimepiride, or metformin\n* History of diabetic ketoacidosis or type 1 diabetes mellitus\n* History of pancreas or beta-cell transplantation\n* History of active proliferative diabetic retinopathy\n* History of hereditary glucose-galactose malabsorption or primary renal glucosuria\n* Renal disease requiring treatment with immunosuppressive therapy within the past 12 months before screening or a history of dialysis or renal transplant\n* Taken thiazolidinedione therapy in the past 16 weeks before screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to Week 52","description":"The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.82","spread":"0.039"},{"groupId":"OG001","value":"-0.93","spread":"0.039"},{"groupId":"OG002","value":"-0.81","spread":"0.039"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Experiencing at Least 1 Hypoglycemic Event From Baseline to Week 52","description":"The table below shows the percentage of patients who experienced at least 1 documented hypoglycemic event from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in percentages.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"4.9","spread":null},{"groupId":"OG002","value":"34.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Body Weight From Baseline to Week 52","description":"The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean percent change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"0.2"},{"groupId":"OG001","value":"-4.7","spread":"0.2"},{"groupId":"OG002","value":"1.0","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c From Baseline to Week 104","description":"The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 104 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.65","spread":"0.042"},{"groupId":"OG001","value":"-0.74","spread":"0.042"},{"groupId":"OG002","value":"-0.55","spread":"0.043"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":483},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Hypoglycaemia","Diarrhoea","Urinary tract infection"]}}}